These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16240894)

  • 21. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.
    Fleshner N; Gomella LG; Cookson MS; Finelli A; Evans A; Taneja SS; Lucia MS; Wolford E; Somerville MC; Rittmaster R;
    Contemp Clin Trials; 2007 Nov; 28(6):763-9. PubMed ID: 17573244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
    Andriole GL; Marberger M; Roehrborn CG
    J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design.
    Siami P; Roehrborn CG; Barkin J; Damiao R; Wyczolkowski M; Duggan A; Major-Walker K; Morrill BB;
    Contemp Clin Trials; 2007 Nov; 28(6):770-9. PubMed ID: 17761460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.
    Reed AB; Parekh DJ
    Curr Opin Urol; 2009 May; 19(3):238-42. PubMed ID: 19318950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnosis and management of benign prostatic hyperplasia.
    Edwards JL
    Am Fam Physician; 2008 May; 77(10):1403-10. PubMed ID: 18533373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.
    Issa MM; Runken MC; Grogg AL; Shah MB
    Am J Manag Care; 2007 Feb; 13 Suppl 1():S10-6. PubMed ID: 17295600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.
    Dolder CR
    Ann Pharmacother; 2006 Apr; 40(4):658-65. PubMed ID: 16569804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dutasteride: a new 5-alpha reductase inhibitor for men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Brown CT; Nuttall MC
    Int J Clin Pract; 2003 Oct; 57(8):705-9. PubMed ID: 14627182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and economic outcomes in patients treated for enlarged prostate.
    Naslund MJ; Issa MM; Grogg AL; Eaddy MT; Black L
    Am J Manag Care; 2006 Mar; 12(4 Suppl):S111-6. PubMed ID: 16551204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative analysis of alpha-blocker utilization in combination with 5-alpha reductase inhibitors for enlarged prostate in a managed care setting among Medicare-aged men.
    Issa MM; Lin PJ; Eaddy MT; Shah MB; Davis EA
    Am J Manag Care; 2008 May; 14(5 Suppl 2):S160-6. PubMed ID: 18611090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Benign prostatic hyperplasia: medical therapy].
    Schlenker B; Gratzke C; Weidlich P; Seitz M; Reich O; Stief CG
    MMW Fortschr Med; 2007 Aug; 149(33-34):29-31; quiz 32. PubMed ID: 17912863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical management of benign prostatic hypertrophy.
    Nix JW; Carson CC
    Can J Urol; 2007 Dec; 14 Suppl 1():53-7. PubMed ID: 18163946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
    Dörsam J; Altwein J
    Prostate Cancer Prostatic Dis; 2009; 12(2):130-6. PubMed ID: 19030020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Definition of at-risk patients: dynamic variables.
    Emberton M
    BJU Int; 2006 Apr; 97 Suppl 2():12-5; discussion 21-2. PubMed ID: 16507047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonsurgical treatment of prostatic hyperplasia.
    Geller J
    Cancer; 1992 Jul; 70(1 Suppl):339-45. PubMed ID: 1376202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
    Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
    Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 5alpha-reductase inhibition for men with enlarged prostate.
    Issa MM; Kraft KH
    J Am Acad Nurse Pract; 2007 Aug; 19(8):398-407. PubMed ID: 17655569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of benign prostatic hyperplasia by the primary care physician in the 21st century: the new paradigm.
    Barkin J
    Can J Urol; 2008 Aug; 15 Suppl 1():21-30; discussion 30. PubMed ID: 18700062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.